Form 8-K - Current report:
SEC Accession No. 0001193125-23-254549
Filing Date
2023-10-12
Accepted
2023-10-12 06:04:34
Documents
16
Period of Report
2023-10-11
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d559822d8k.htm   iXBRL 8-K 37173
2 EX-3.1 d559822dex31.htm EX-3.1 27132
3 EX-3.2 d559822dex32.htm EX-3.2 179969
4 EX-10.1 d559822dex101.htm EX-10.1 71228
  Complete submission text file 0001193125-23-254549.txt   553413

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA amam-20231011.xsd EX-101.SCH 4114
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE amam-20231011_def.xml EX-101.DEF 14881
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE amam-20231011_lab.xml EX-101.LAB 24931
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amam-20231011_pre.xml EX-101.PRE 15789
10 EXTRACTED XBRL INSTANCE DOCUMENT d559822d8k_htm.xml XML 6334
Mailing Address 10975 NORTH TORREY PINES ROAD LA JOLLA CA 92037
Business Address 10975 NORTH TORREY PINES ROAD LA JOLLA CA 92037 (858) 875-2400
Ambrx Biopharma Cayman, Inc. (Filer) CIK: 0001836056 (see all company filings)

EIN.: 571147346 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40505 | Film No.: 231321655
SIC: 2836 Biological Products, (No Diagnostic Substances)